Developping gene therapies and innovative treatments for nerve-related diseases

Notre mission

Nervosave Therapeutics  develops a platform of local gene therapies that slow, stop and reverse a broad range of diseases involving peripheral nerves.

Our first aim is to develop best in class gene therapy for Charcot-Marie-Tooth (CMT) disease 1A and beyond for all CMT diseases.

Our platform has game-changing potential in several devastating diseases with clear therapeutic needs such as neuralgias, diabetic peripheral neuropathy and other degenerative diseases involving nerves.